ALG125097

**ALG125097** is an investigational **small interfering RNA** therapeutic from **Aligos Therapeutics** for **chronic hepatitis B**. It is part of Aligos' HBV functional-cure portfolio and was designed to reduce expression of hepatitis B viral products, with available public information indicating inhibition of **hepatitis B surface antigen** production or release through an **RNA interference** mechanism directed against HBV transcripts. Company materials describe preclinical antiviral activity in HBV mouse models, and Aligos had indicated plans to evaluate the candidate in early umbrella-style clinical development before potential combination studies with other HBV agents. Public reporting later suggested the program was no longer being actively advanced, with Aligos focusing its remaining HBV development efforts on other assets.